UnicoCell

UnicoCell has been focusing on the development and application of new stem cell drugs for more than 10 years. Our cell production plant has been approved by TFDA under GTP guidance for Human Tissue Banks and human clinical trials, verified as a CPU (Cell Processing Unit) under RASMET (“The Regulation Governing the Application of Specific Medical Examination Technique and Medical Device”), and obtained the Accreditation Certificate of Foreign Cell Processor from Japan MHLW (Ministry of Health, Labor and Welfare).

With the same high standard of quality systems required by clinical trials, UnicoCell has partnered with major hospitals in Taiwan on autologous stem cell therapy for knee osteoarthritis.